The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder.
Marcel O Bonn-Miller, Megan Brunstetter, Alex Simonian, Mallory Loflin, Ryan Vandrey, Kimberly A Babson, Hal Wortzel
Cannabis and Cannabinoid Research April 2022 DOI: 10.1089/can.2020.0056 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Prospective longitudinal observational study Randomized Placebo-controlled Peer reviewed |
|---|---|
| Sample size | 150 |
| Population | Adults diagnosed with PTSD, including dispensary-obtained cannabis users and non-using controls |
| Intervention | Dispensary-obtained cannabis |
| Duration | 1 year, with assessments every 3 months |
| Topics | Cannabis PTSD |
| Keywords | Control Longitudinal |
| Key findings | Cannabis users showed a greater decrease in PTSD symptom severity over one year than controls (group-by-time interaction -0.32, 95% CI -0.59 to -0.05) and were 2.57 times more likely to no longer meet DSM-5 criteria for PTSD at follow-up (95% CI 1.12-6.07). The authors suggest dispensary cannabis might hold promise as an alternative PTSD treatment, while calling for randomized placebo-controlled trials. |
Abstract
Introduction: Given the increasing availability and use of cannabis among individuals with post-traumatic stress disorder (PTSD) and the addition of PTSD as an eligible diagnosis in several U.S. medical cannabis programs, the efficacy of dispensary-obtained cannabis needs to be thoroughly examined.
Materials and Methods: This prospective study assessed PTSD symptoms and functioning every 3 months over the course of a year in two samples of participants diagnosed with PTSD: (1) those with PTSD using dispensary-obtained cannabis (cannabis users) and (2) those with PTSD, who do not use cannabis (controls). Linear mixed-effects models and generalized estimating equations tested whether trajectories of symptoms differed between the two subsamples.
Results: A total of 150 participants (mean [standard deviation] age, 50.67 [15.26] years; 73% male) were enrolled in the study. Over the course of 1 year, the cannabis users reported a greater decrease in PTSD symptom severity over time compared to controls [group×time interaction=-0.32 (95% confidence interval [CI]=-0.59 to -0.05, R2=0.13; t=-2.35, p=0.02). Participants who used cannabis were 2.57 times more likely to no longer meet DSM-5 criteria for PTSD at the end of the study observation period compared to participants who did not use cannabis (95% CI=1.12-6.07; p=0.03).
Conclusions: This study provides evidence that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD. Randomized placebo-controlled trials are needed to assess safety and determine how different preparations of cannabis impact PTSD and functioning.
Comparable studies
Other observational and cohort studies on PTSD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with Chronic Posttraumatic Stress Disorder Women with chronic PTSD secondary to sexual assault | 2008 | Observational cohort | n = 6 |
| An Ambulatory Polysomnography Study of the Post-traumatic Nightmares of Post-traumatic Stress Disorder Treatment-seeking veterans, current serving military members, and emergency service... | 2017 | Observational study using ambulatory polysomnography | n = 35 |
| Increased Mastery Elements Associated With Imagery Rehearsal Treatment for Nightmares in Sexual Assault Survivors With PTSD. Female sexual assault survivors with chronic nightmares | 2004 | Observational cohort | n = 44 |
| Posttraumatic stress symptoms following near-death experiences. Persons who report near-death experiences and those who came close to death without NDEs | 2001 | Observational study | |
| Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Outpatients with treatment-resistant depression and PTSD | 2018 | Retrospective review | n = 37 |
Citations in the library
Cited by 6
- The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial PLoS One March 17, 2021
- Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. Pharmacology & Therapeutics November 1, 2022
- High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. Annals of Internal Medicine October 1, 2025
- Challenges and considerations for treating PTSD with medicinal cannabis: the Australian clinician's perspective. Expert Review of Clinical Pharmacology 2023
- Impaired mnemonic pattern separation associated with PTSD symptoms paradoxically improves with regular cannabis use npj Mental Health Research April 24, 2025
and 1 more in the library
Cites 5
- Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers Current Pharmaceutical Design September 12, 2012
- Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption. European Neuropsychopharmacology June 2015
- The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology January 2015
- Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clinical drug investigation August 2014
- Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. Current Pharmaceutical Design 2014